S
16.15
1.35 (9.12%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Summit Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.4 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.11 |
Select this tab to load the latest available analysis.
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 84.32% |
| % Held by Institutions | 13.52% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Oct 2026 | CNBC | AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |